Showing posts with label gene. Show all posts
Showing posts with label gene. Show all posts

Tuesday, September 24, 2013

0 Association of 5-lipoxygenase gene polymorphisms with bronchial asthma






























Association of 5-lipoxygenase gene polymorphisms with bronchial asthma


Authors:
 Chunying Bai, Xiaoming Yu, Rui Yun, Tiewei Shi, Chaojun Zhang, Jing Zhou, Sachurangui, Lijuan Tong, Xiujun Li, Lifeng Gao


Affiliations:
 Molecular Medicine Research Center, School of Medical Science, Chifeng University, P.R. China, Department of Pediatrics, First Affiliated Hospital of Chifeng University, P.R. China, Department of Pneumology, First Affiliated Hospital of Chifeng University, P.R. China, Department of Pediatrics, Chifeng City Hospital, Chifeng, Inner Mongolia, P.R. China


Published online on:
 Monday, September 17, 2012


Doi:
 10.3892/etm.2012.712


Pages:
 967-971


Abstract:

Leukotrienes are important pro-inflammatory mediators in bronchial asthma (BA) and are derived from arachidonic acid by the action of 5-lipoxygenase (5-LO). We investigated the association of 5-LO gene polymorphisms with BA. Thirty-six single-nucleotide polymorphisms (SNPs) of the 5-LO gene, as referenced in the dbSNP gene bank, were analyzed with sequencing and allele-specific PCR (AS-PCR) in genomic DNA from individuals with BA and controls. Of these 36 SNPs, 4 were identified in our study. The c.760 G>A (E254K) (rs2228065) was detected in 15 out of 215 BA patients and 6 out of 212 controls (PA), rs116961353 (c.780G>A) and rs2229136 (c.1728 A>G) between individuals with BA and controls (P>0.05). With our designed primers for AS-PCR, the detection of the 5-LO gene E254K polymorphism was clear and accurate, and the genotype was directly distinguished. Our findings contribute to the evaluation of one of the genetic risk factors for BA and we report an accurate and simple method to rapidly detect the 5-LO E254K polymorphism. It is important to further study the correlation between drug response in BA patients using 5-LO inhibitors with the E254K polymorphism in the clinic.0>











Experimental and Therapeutic Medicine

December 2012
Volume 4 Number 6




Viewing options:

Sign up for eToc alerts
Share this article:




 




Monday, September 16, 2013

0 Airway gene expression in COPD is dynamic with inhaled corticosteroid treatment and reflects biological pathways associated with disease activity




Thorax doi:10.1136/thoraxjnl-2012-202878




  • Chronic obstructive pulmonary disease



  • Original article



Airway gene expression in COPD is dynamic with inhaled corticosteroid treatment and reflects biological pathways associated with disease activity


Open Access















  1. Dirkje S Postma1,2


+Author Affiliations




  1. 1Department of Pulmonary Diseases, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands




  2. 2GRIAC (Groningen Research Institute for Asthma and COPD), University of Groningen, University Medical Center Groningen, Groningen, The Netherlands




  3. 3Division of Computational Biomedicine, Department of medicine, Boston University School of Medicine, Boston, Massachusetts, USA




  4. 4Department of Pathology and Medical Biology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands




  5. 5Department of Pulmonary Diseases, Leiden University Medical Center, Leiden, The Netherlands




  6. 6Department of Respiratory Medicine, F5-259, Academic Medical Centre, University of Amsterdam, Amsterdam, The Netherlands




  7. 7Department of Pathology and Laboratory Medicine, Boston University School of Medicine, Boston, Massachusetts, USA





  1. Correspondence toDr M van den Berge, Department of Pulmonary Diseases, University of Groningen, University Medical Center Groningen, Hanzeplein 1, Groningen 9700 RB, The Netherlands;m.van.den.berge@umcg.nl




  • Received 16 October 2012


  • Revised 4 June 2013


  • Accepted 30 June 2013


  • Published Online First 7 August 2013




Abstract



Background A core feature of chronic obstructive pulmonary disease (COPD) is the accelerated decline in forced expiratory volume in one second (FEV1). The recent Groningen and Leiden Universities study of Corticosteroids in Obstructive Lung Disease (GLUCOLD) study suggested that particular phenotypes of COPD benefit from fluticasone±salmeterol by reducing the rate of FEV1 decline, yet the underlying mechanisms are unknown.



Methods Whole-genome gene expression profiling using the Affymetrix Gene ST array (V.1.0) was performed on 221 bronchial biopsies available from 89 COPD patients at baseline and after 6 and 30 months of fluticasone±salmeterol and placebo treatment in GLUCOLD.



Results Linear mixed effects modelling revealed that the expression of 138 genes decreased, whereas the expression of 140 genes significantly upregulated after both 6 and 30 months of treatment with fluticasone±salmeterol versus placebo. A more pronounced treatment-induced change in the expression of 50 and 55 of these 278 genes was associated with a lower rate of decline in FEV1 and Saint George Respiratory Questionnaire, respectively. Genes decreasing with treatment were involved in pathways related to cell cycle, oxidative phosphorylation, epithelial cell signalling, p53 signalling and T cell signalling. Genes increasing with treatment were involved in pathways related to focal adhesion, gap junction and extracellular matrix deposition. Finally, the fluticasone-induced gene expression changes were enriched among genes that change in the airway epithelium in smokers with versus without COPD in an independent data set.



Conclusions The present study suggests that gene expression in biological pathways of COPD is dynamic with treatment and reflects disease activity. This study opens the gate to targeted and molecular phenotype-driven therapy of COPD.

This Article



This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 3.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See:http://creativecommons.org/licenses/by-nc/3.0/








Sunday, September 15, 2013

0 HTR4 gene structure and altered expression in the developing lung

Open Access


Research


HTR4 gene structure and altered expression in the developing lung



Emily Hodge, Carl P Nelson, Suzanne Miller, Charlotte K Billington, Ceri E Stewart, Caroline Swan, Anders Malarstig,Amanda P Henry, Catherine Gowland, Erik Melén, Ian P Hall and Ian Sayers











For all author emails, please log on.









Respiratory Research 2013, 14:77 doi:10.1186/1465-9921-14-77

Published: 26 July 2013





Abstract (provisional)


Background


Meta-analyses of genome-wide association studies (GWAS) have identified single nucleotide polymorphisms (SNPs) spanning the 5-hydroxytryptamine receptor 4 (5-HT4R) gene (HTR4) associated with lung function. The aims of this study were to i) investigate the expression profile of HTR4 in adult and fetal lung tissue and cultured airway cells, ii) further define HTR4 gene structure and iii) explore the potential functional implications of key SNPs using a bioinformatic approach.

Methods


Following reverse transcription (RT)-PCR in human brain, 5[prime] rapid amplification of cDNA ends (5[prime] RACE) was used to examine the exonic structure of HTR4 at the 5[prime] end. Quantitative (Q)-PCR was used to quantify HTR4 mRNA expression in total RNA from cultured airway cells and whole lung tissue. Publically available gene microarray data on fetal samples of estimated gestational age 7–22 weeks were mined for HTR4 expression. Immunohistochemistry (IHC; in adult and fetal lung tissue) and a radioligand binding assay (in cultured airway cells) were used to analyze 5-HT4R protein expression.

Results



IHC in adult lung, irrespective of the presence of chronic obstructive pulmonary disease (COPD), suggested low level expression of 5-HT4R protein, which was most prominent in alveolar pneumocytes. There was evidence of differential 5-HT4R protein levels during gestation in fetal lung, which was also evident in gene expression microarray data. HTR4 mRNA expression, assessed by Q-PCR, was -0.5% relative to brain in total adult lung tissue and in human airway smooth muscle (HASM) and bronchial epithelial cells (HBEC) derived from adult donors. Radioligand binding experiments also indicated that HBEC and HASM cells did not express a significant 5-HT4R population. 5[prime] RACE in brain identified a novel N-terminal variant, containing an extended N-terminal sequence. The functional significance of key HTR4 SNPs was investigated using the encyclopedia of DNA elements consortium (ENCODE) dataset. These analyses identified multiple alterations in regulatory motifs for transcription factors implicated in lung development, including Foxp1.


Conclusions


Taken together, these data suggest a role for HTR4 in lung development, which may at least in part explain the genetic association with lung function.






The complete article is available as a provisional PDF. The fully formatted PDF and HTML versions are in production.